Estradot Transdermal Patches

Home
Medicines
Estradot Transdermal Patches

Name:
Estradot Transdermal Patches
Company:
Novartis Ireland Limited
Active Ingredients:
Estradiol Hemihydrate
Legal Category:
Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 29/08/19

Company Products

Medicine Name	Active Ingredients
Medicine Name Aclasta 5 mg solution for infusion	Active Ingredients Zoledronic acid monohydrate
Medicine Name Afinitor Tablets	Active Ingredients Everolimus
Medicine Name Aimovig	Active Ingredients Erenumab
Medicine Name Atriance 5 mg/ml solution for infusion	Active Ingredients Nelarabine
Medicine Name Azarga 10mg/ml + 5mg/ml eye drops, suspension	Active Ingredients Brinzolamide, Timolol Maleate
Medicine Name Azopt 10mg/ml eye drops suspension	Active Ingredients Brinzolamide
Medicine Name Cataflam 50 mg Coated Tablets	Active Ingredients Diclofenac Potassium
Medicine Name Certican Tablets	Active Ingredients Everolimus
Medicine Name CILOXAN 3 mg/ml ear drops, solution	Active Ingredients Ciprofloxacin hydrochloride
Medicine Name Co-Diovan 160 mg/12.5 mg film-coated tablets	Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Co-Diovan 160mg/25mg film-coated tablets	Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Co-Diovan 320mg/12.5mg film-coated tablets	Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Co-Diovan 320mg/25mg film-coated tablets	Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Co-Diovan 80mg/12.5mg film-coated tablets	Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Cosentyx 150 mg solution for injection in pre-filled pen	Active Ingredients secukinumab
Medicine Name Desferal 500mg Vials	Active Ingredients Desferrioxamine Mesylate
Medicine Name Diovan 160 mg film-coated tablets	Active Ingredients Valsartan
Medicine Name Diovan 320mg film-coated tablets	Active Ingredients Valsartan
Medicine Name Diovan 3mg/ml Oral Solution	Active Ingredients Valsartan
Medicine Name Diovan 40 mg film-coated tablets	Active Ingredients Valsartan
Medicine Name Diovan 80 mg film-coated tablets	Active Ingredients Valsartan
Medicine Name DuoTrav Eye Drops Solution	Active Ingredients Timolol Maleate, Travoprost
Medicine Name Entresto 24mg/26mg, 49mg/51mg and 97mg/103mg film-coated tablets	Active Ingredients Sacubitril, Valsartan
Medicine Name Estradot Transdermal Patches	Active Ingredients Estradiol Hemihydrate
Medicine Name Eucreas 50mg / 850mg and 50mg / 1000mg film-coated tablets	Active Ingredients Metformin Hydrochloride, Vildagliptin

Items Per Page :

1 - 0 of 116 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 29 August 2019 PIL

Reasons for updating

Change to section 4 - how to report a side effect
Change to section 6 - what the product looks like and pack contents

Updated on 29 August 2019 SmPC

Reasons for updating

Change to section 6.1 - List of excipients

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 8 April 2019 SmPC

Reasons for updating

File format updated to PDF

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 27 October 2018 PIL

Reasons for updating

Change to section 6 - marketing authorisation holder

Updated on 13 July 2018 SmPC

Reasons for updating

Change to section 7 - Marketing authorisation holder
Change to section 8 - Marketing authorisation number(s)
Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 13 June 2016 PIL

Reasons for updating

New PIL for new product

Updated on 13 June 2016 PIL

Reasons for updating

Change to warnings or special precautions for use
Change of special precautions for disposal

Updated on 6 June 2016 SmPC

Reasons for updating

Change to section 4.4 - Special warnings and precautions for use
Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.4: deleted "Long-term (at least 5-10 years) use of oestrogen-only HRT products has been associated with a slightly increased risk of ovarian cancer (see section 4.8)." and added "

Epidemiological evidence from a large meta-analysis suggests a slightly increased risk in women taking oestrogen-only or combined oestrogen-progestagen HRT, which becomes apparent within 5 years of use and diminishes over time after stopping." under the Ovarian cancer heading.

Section 4.8: deleted " In the Million Women Study 5 years of HRT resulted in 1 extra case per 2,500 users." and added "

A meta-analysis from 52 epidemiological studies reported an increased risk of ovarian cancer in women currently using HRT compared to women who have never used HRT (RR 1.43, 95% CI 1.31-1.56). For women aged 50 to 54 years taking 5 years of HRT, this results in about 1 extra case per 2000 users. In women aged 50 to 54 who are not taking HRT, about 2 women in 2000 will be diagnosed with ovarian cancer over a 5-year period."

Updated on 6 June 2016 SmPC

Reasons for updating

New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 15 April 2016 SmPC

Reasons for updating

Change to section 6.6 - Special precautions for disposal and other handling

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 6.6 - Replaced "No special requirements" with "Used transdermal patches should be folded in half with the adhesive side inwards, and discarded safely and out of the reach and sight of children. Any used or unused transdermal patches should be disposed of in accordance with local requirements or returned to the pharmacy, preferably in the original packaging."

Updated on 1 May 2015 PIL

Reasons for updating

Change to warnings or special precautions for use
Change to side-effects
Change to drug interactions
Change to date of revision

Updated on 13 April 2015 SmPC

Reasons for updating

Change to section 4.4 - Special warnings and precautions for use
Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Change to section 4.8 - Undesirable effects
Change to section 5.1 - Pharmacodynamic properties
Change to section 5.2 - Pharmacokinetic properties
Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.4 - revised to include information on Severe anaphylactic/anaphylactoid reactions and a warning for patients with angioedema.
Section 4.5 - updated to include the following sentence: Estradiol is predominantly metabolized by CYP3A4, hence concomitant administration of inhibitors of CYP3A4 such as ketoconazole, erythromycin may result in increase in the exposure of estradiol.
Section 4.8 - additional ADRs included in table as well as information for reporting of suspected adverse reactions.
Section 5.1 - spelling of vertebral corrected.
Section 5.2 - heading changed to Biotransformation/Metabolism.

Updated on 21 May 2012 SmPC

Reasons for updating

Change to section 2 - Qualitative and quantitative composition
Change to section 4.3 - Contraindications
Change to section 4.4 - Special warnings and precautions for use
Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Change to section 4.8 - Undesirable effects
Change to section 5.2 - Pharmacokinetic properties
Change to section 5.3 - Preclinical safety data

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

SmPC has been revised to bring it in line the with the European Core Data Sheet for HRT products.

Updated on 21 May 2012 PIL

Reasons for updating

Change to warnings or special precautions for use
Change to storage instructions
Change to side-effects

Updated on 16 November 2011 PIL

Reasons for updating

Change to marketing authorisation holder

Updated on 11 July 2011 PIL

Reasons for updating

Change due to user-testing of patient information

Updated on 12 April 2007 SmPC

Reasons for updating

Change to section 1 - Name of medicinal product
Change to section 2 - Qualitative and quantitative composition
Change to section 4.1 - Therapeutic indications
Change to section 4.2 - Posology and method of administration
Change to section 4.3 - Contraindications

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Additional Information in 1, 2, 4.1, 4.2, 4.3

Updated on 7 March 2006 SmPC

Reasons for updating

Change to section 4.4 - Special warnings and precautions for use
Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 22 November 2005 PIL

Reasons for updating

Change to warnings or special precautions for use
Improved electronic presentation

Updated on 9 September 2005 SmPC

Reasons for updating

Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 24 August 2004 PIL

Reasons for updating

New PIL for medicines.ie

Updated on 26 June 2003 SmPC

Reasons for updating

New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)